UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 264, 2026

PACS GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-42011

92-3144268

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification Number)

90 S. 400 W. Suite 700

Salt Lake City, Utah 84101

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (801) 447-9829

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Common Stock, $0.001 par value per share

PACS

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 25.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~February 26~~March 4, 2026, the Board of Directors (the “Board”) of PACS Group, Inc. (the “Company”), ~~issued~~upon athe ~~press~~recommendation ~~release~~of ~~announcing~~its ~~financial~~Nominating ~~results~~and ~~for~~Corporate ~~its~~Governance ~~fourth~~Committee, ~~quarter~~appointed ~~and~~Patrick ~~year~~H. ~~ended~~Conway, ~~December 31~~MD, ~~2025~~MSc to the Board, effective immediately. ADr. ~~copy~~Conway ofwill serve as a Class III director for a term expiring at the ~~press~~Company’s ~~release~~annual meeting of stockholders to be held in 2027 and until his successor is ~~being~~duly ~~furnished~~elected asand ~~Exhibit~~qualified ~~99.1~~or tountil ~~this~~his ~~Current~~earlier ~~Report~~death, onresignation, ~~Form~~disqualification ~~8-K~~or removal.

~~The~~Dr. ~~information~~Conway ~~contained~~will participate in ~~this~~the ~~Current~~compensation ~~Report~~program onfor ~~Form 8~~non-Kemployee ~~(including~~directors ~~Exhibit~~described ~~99.1~~in ~~hereto)~~the ~~shall~~Company’s ~~not~~Definitive beProxy ~~deemed~~Statement “filed” ~~for~~with ~~purposes of Section 18 of~~ the Securities ~~Exchange~~and ~~Act of 1934, as amended (the “~~Exchange ~~Act”)~~Commission oron ~~otherwise~~November ~~subject~~25, to2025. ~~the~~In ~~liabilities of that section~~addition, ~~nor~~Dr. ~~shall~~Conway itwill beenter ~~deemed~~into ~~incorporated by reference in any filing under~~ the ~~Securities~~Company’s ~~Act~~standard ofindemnification ~~1933,~~agreement asfor ~~amended,~~directors orand ~~the Exchange Act, except as expressly set forth by specific reference in such a filing~~officers.

There is no arrangement or understanding pursuant to which Dr. Conway was appointed to the Board. There are no family relationships between Dr. Conway and any director or executive officer of the Company as defined in Item 401(d) of Regulation S-K, and Dr. Conway has no direct or indirect material interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On March 5, 2026, the Company issued a press release (the “Press Release”) announcing the director appointment described in Item 5.02 of this Current Report on Form 8-K. A copy of the Press Release is attached hereto as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.			Description
99.1			Press Release of the Company dated ~~February~~March 265, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PACS GROUP, INC.
Date: February 26, 2026	By:	/s/ Mark Hancock
Date: March 5, 2026	By:	/s/ Jason Murray
		Mark Hancock
		Jason Murray
		Director, Executive Vice Chairman, and Interim Chief Financial Officer
		Director, Chairman, and Chief Executive Officer

Filing Compare · PACS Group, Inc.